Role of dual biomarkers and uterine artery doppler study in predicting PIH and IUGR in antenatal patients registered in a tertiary care centre

Alka C. Bapat¹*, Rupesh Kashikar², Shashi R. Goyal¹

¹Department of Obstetrics and Gynecology, ²Department of Ultrasonography, Bombay Hospital Institute of Medical Education and Research, Mumbai, Maharashtra, India

Received: 17 December 2020
Revised: 19 January 2021
Accepted: 22 January 2021

*Correspondence:
Dr. Alka C. Bapat.
E-mail: bapat.alka@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: The incidence of IUGR is between 3 to 7%, whereas that of Hypertensive disorders of pregnancy is about 10% of pregnant women around the world. These conditions are associated with a high rate of perinatal morbidity and mortality, posing a need for the detection of the potential causes of maternal and foetal morbidity and mortality and for the prediction of these conditions early during pregnancy.

Methods: Patients with first antenatal visit before 10 weeks gestation underwent routine NT scan between 11–13 weeks with bilateral UAD-RI of the maternal uterine arteries. The placental volume was assessed. Serum dual biomarker test (β hCG and PAPP-A) was performed after this scan and analysed as multiples of median (MoM). Blood pressure was recorded at every ANC visit till 2 weeks after delivery. Neonatal head and chest circumference, birth length and weight were recorded.

Results: The mean values of PAPP-A levels of Non-PIH and PIH groups were 1.32±0.91 MoM and 0.68±0.39 MoM respectively, showing statistically significant difference. The serum PAPP-A levels showed statistically significant difference between Non-IUGR and IUGR groups (1.24±0.87 MoM and 0.46±0.20 MoM respectively).

Conclusions: In our study, PAPP-A level is observed as a good indicator for possible prediction of PIH and IUGR whereas levels of β hCG and UAD-RI were not good predictors. The role of Placental volume in prediction of IUGR needs to be explored further with larger sample size. Future studies are needed with a larger group with inclusion of measurement of PI values.

Keywords: Dual biomarkers, IUGR, PIH, Uterine artery doppler - resistivity index (UAD-RI)

INTRODUCTION

Hypertension is the one of the common medical problem complicating nearly 10% of pregnancies.¹ The national incidence of Pregnancy Induced Hypertension (PIH) is 15.2% in Indian population. PIH is said to occur when there is a rise of blood pressure to ≥ 140/90 mm Hg during gestation, as per the ISSHP.²

In the hypertensive disorders’ spectrum in pregnancy, preeclampsia and eclampsia are responsible for about 10.0% of maternal deaths, annually, with an additional 20-30 women suffering significant morbidity for every maternal death.³ Foetuses of these mothers are at greater risk of IUGR, prematurity and intrauterine demise.⁴

IUGR – intra-uterine growth restriction, also known as foetal growth restriction (FGR) is defined as the pathologic inhibition of intrauterine foetal growth and failure of the foetus to achieve its normal growth potential.⁵

IUGR, with an incidence between 3 to 7%, is diagnosed in antenatal period if, sonographically estimated foetal weight <10th percentile for gestational age or with a documentation of foeto-placental insufficiency.⁶,⁷
Increased foetal and neonatal mortality and morbidity as well as adult-onset pathological conditions are also often attributed to IUGR due to associated epigenetic changes.

Currently no treatment is available that can reverse the pathophysiological events associated with preeclampsia and so also for IUGR.9,10 Amongst the several screening methods, uterine artery Doppler (UAD) ultrasound is used for the indirect assessment of uteroplacental circulation from early gestation.10 UAD is considered as a potential screening tool for detection of preeclampsia and IUGR.10,11

β human chorionic gonadotropin (hCG) hormone secreted by the placenta has been linked to foetal growth whereas Pregnancy-associated plasma protein-A (PAPP-A) is a known promoter of angiogenesis.12,13 According to Poon et al. (2009, 2010), when the pregnant women first visit the hospital, i.e., at 11-13 weeks gestational age, sono graphic and biochemical testing may be carried out for gestational hypertensive disorders.14-16 Patil et al. (2014) observed low levels of PAPP-A in first trimester with infant death, IUGR, preterm birth and pre-eclampsia in chromosomally normal foetuses.13 They also observed raised PAPP-A levels and nuchal translucency to be associated with specific structural abnormalities and genetic syndromes.

Linking UAD study to the booking tests (Nuchal scan and Dual biochemical markers) could probably be able to identify a high-risk group, which in turn would help in initiating prophylactic therapies as early as 12–14 weeks into the pregnancy.

METHODS

This was a prospective, observational study carried out in the department of ‘Obstetrics and Gynaecology’ of a private tertiary care centre. Approval for the study was obtained from the Institutional Ethics Committee Review Board in 2017. Antenatal women visiting OPD, with first visit before 10 weeks of gestation and the same falling within 1st November 2017 and 30th April 2019 were enrolled. Those patients with pregnancy between 11-13 weeks, confirmed by LMP and early scan, with a single live intrauterine pregnancy after having given written informed consent were included. Patients with age ≥40 years, multi-foetal pregnancy, pre pregnancy BMI ≥30.0, with pre-existing hypertension or infections, smoking, drinking habits or other addictions were excluded.17 Patients developing hypertension before 20 weeks and those lost to follow up or with diagnosis of IUFD were excluded from analysis. The studies undertaken by Narang S. et al and Spencer K. et al were used as reference for calculating the sample size.18,19 The target sample size was not less than 30 patients. Of the 35 patients enrolled in the research study, 3 were lost to follow up and 1 fell in the exclusion criteria, thus 4 were excluded. Data analysis of the remaining 31 patients was carried out.

The enrolled patients underwent additional UAD study (RI values of the right and left maternal uterine arteries) and placental volume assessment (calculated by measurements of length, width, and thickness) with routine NT scan and Dual biomarker test between 11.0-13.0 weeks.20-22 The data of dual biomarkers (β hCG and PAPP-A) was converted in multiples of median (MoM) for analysis.23

Blood pressure was recorded at every ANC visit. Required ANC care was provided and follow up was advised with ultrasound scans at 20, 28 and 36 weeks. Maternal BP before and up to 2 weeks after delivery was recorded. Date and mode of delivery, the head and chest circumference along with birth length in centimetres and weight of the neonate in grams were recorded. APGAR score of the new-born at the end of 1, 5 and 10 mins was noted. Any need for admission of the baby to NICU was documented.

Relevant data was analysed by statistician using Microsoft Excel’s in-built functions and two sample t-test was performed using Analysis Tool-pack Add-In, provided in Microsoft Excel.

RESULTS

The results were analysed in terms of demographic data and outcomes along with the UAD-RI screen, Dual Biomarkers and Placental volume.

The outcomes of interest in the study were the development of PIH and IUGR.

### Table 1: Frequency of outcomes in terms of PIH and IUGR.

| Outcome | Frequency | % |
|---------|-----------|---|
| PIH     | 6         | 19.35 |
| IUGR    | 2         | 6.45  |

The outcomes evaluated were found to occur in 22.58% of patients. One patient (3.2 le total number of patients studied) had both PIH and IUGR adverse effects.

The RI was recorded separately for the right and left uterine arteries and mean RI calculated. The values recorded are depicted in tabular form.

### Table 2: Average UAD RI in both Ut arteries.

| UAD (Doppler values) | RI | Mean ± SD |
|----------------------|----|-----------|
| Right                | 0.66±0.15 | |
| Left                 | 0.66±0.14 | |

One patient had nothing in unilateral uterine artery - in this case, the right, while 1 had bilateral notching of Ut arteries. However, in the study none of these 2 patients developed any complications of PIH or IUGR.
The mean value of $\beta$ hCG in terms of MoM was 1.16±0.89 whereas that for PAPP-A was 1.18±0.86 for the entire patient group.

The average placental volume recorded in the study was 46.62±16.11 cc.

The mean values of the Dual biomarkers in MoM, UAD-RI, Placental volume in cc. in PIH, Non PIH and IUGR and Non IUGR groups are given in the Table below.

| Parameters | PIH | Non PIH | IUGR | Non IUGR |
|------------|-----|---------|------|----------|
| PAPP-A     | 0.68±0.38 | 1.32±0.91 | 0.46±0.2 | 1.24±0.87 |
| $\beta$ hCG | 0.95±0.65 | 1.22±0.95 | 1.0±0.64 | 1.18±0.92 |
| UAD-RI avg. | 0.60±0.17 | 0.68±0.1 | 0.57±0.095 | 0.67±0.12 |
| Placental volume | 43.2±16.16 | 47.44±16.32 | 24.35±8.13 | 48.15±0 |

The differences of the master-chart record are available in the dissertation submitted by the author to the Maharashtra University of Health Sciences.24

There was a statistically significant correlation between low PAPP-A levels and development of PIH and IUGR.

| Parameters | PIH | Non PIH | IUGR | Non IUGR |
|------------|-----|---------|------|----------|
| PAPP-A     | 0.68±0.38 | 1.32±0.91 | 0.46±0.2 | 1.24±0.87 |
| $\beta$ hCG | 0.95±0.65 | 1.22±0.95 | 1.0±0.64 | 1.18±0.92 |
| UAD-RI avg. | 0.60±0.17 | 0.68±0.1 | 0.57±0.095 | 0.67±0.12 |
| Placental volume | 43.2±16.16 | 47.44±16.32 | 24.35±8.13 | 48.15±0 |

The difference in two group values is statistically significant at confidence level $\alpha = 0.05$. Thus, PAPP-A is a potential indicator of PIH. However, since the variability in the Non-PIH group is high, it is difficult to propose a flag-post PAPP-A level for predicting PIH. Value of less than 1.0 MoM would be an indication of likelihood of impending PIH.

The difference in two group values is statistically significant at confidence level $\alpha = 0.05$. Thus, PAPP-A is a potential indicator of PIH. PAPP-A levels of less than 0.6 MoM would be an indication of impending IUGR outcome. However, since the variability in the Non-IUGR group is high, it is difficult to propose a flag-post PAPP-A level for predicting IUGR.

Though the difference in two group values is not statistically significant at $\alpha = 0.05$, the low $p$-value is indicative of weak evidence towards rejection of Null hypothesis. The role of low placental volume conjoined with low PAPP-A MoM values could be valuable indicator of IUGR outcome.

| Parameters | PIH | Non PIH | IUGR | Non IUGR |
|------------|-----|---------|------|----------|
| PAPP-A     | 0.68±0.38 | 1.32±0.91 | 0.46±0.2 | 1.24±0.87 |
| $\beta$ hCG | 0.95±0.65 | 1.22±0.95 | 1.0±0.64 | 1.18±0.92 |
| UAD-RI avg. | 0.60±0.17 | 0.68±0.1 | 0.57±0.095 | 0.67±0.12 |
| Placental volume | 43.2±16.16 | 47.44±16.32 | 24.35±8.13 | 48.15±0 |

The difference in two group values is statistically significant at confidence level $\alpha = 0.05$. Thus, PAPP-A is a potential indicator of PIH. However, since the variability in the Non-PIH group is high, it is difficult to propose a flag-post PAPP-A level for predicting PIH. Value of less than 1.0 MoM would be an indication of likelihood of impending PIH.

The difference in two group values is statistically significant at confidence level $\alpha = 0.05$. Thus, PAPP-A is a potential indicator of PIH. PAPP-A levels of less than 0.6 MoM would be an indication of impending IUGR outcome. However, since the variability in the Non-IUGR group is high, it is difficult to propose a flag-post PAPP-A level for predicting IUGR.

Though the difference in two group values is not statistically significant at $\alpha = 0.05$, the low $p$-value is indicative of weak evidence towards rejection of Null hypothesis. The role of low placental volume conjoined with low PAPP-A MoM values could be valuable indicator of IUGR outcome.

Mean UAD-RI, serum $\beta$ hCG-mean MoM value and placental volume showed no statistically significant correlation between the PIH and non PIH groups.

Serum PAPP-A levels were on the lower side in PIH and for IUGR group than the normal population in the study with statistically significant difference in the marker level.
Mean UAD-Ri, serum β hCG-mean MoM value and Placental volume values did not exhibit statistically significant correlation in patients who developed IUGR and for the patients without IUGR.

**DISCUSSION**

Our study recorded the median age of women who developed PIH to be 27.5 yrs and those who did not develop PIH to be 30 yrs, same as that of all participants. Study published by Muti et al. (2015) showed median age for occurrence of PIH to be 29.0 yrs in their sample. According to this study, affected women were older than the unaffected ones.25

In our study, the mean RI values for the sample were 0.66±0.15 of the right uterine artery and 0.66±0.14 for the left. The mean RI value of right and left arteries was 0.66±0.12. A prospective cohort study comprising singleton pregnancies published by Scanduzzi et al. in 2016 reported Right Ut A RI value as 0.69±0.13, and 0.69±0.12 was reported for the left. The mean RI for both arteries was 0.69 ± 0.1. 26 These values are similar to our findings.

Based on observations in the present study we observed a statistically significant difference in PAPP-A levels of Non-PIH and PIH patient groups. The observed mean value of PAPP-A levels in Non-PIH group was 1.32±0.91 MoM, whereas in PIH group was 0.68±0.39 MoM. The results are in agreement with a prospective cohort study published by Moety et al. (2016), to evaluate the first trimester placental function in predicting PE and IUGR which revealed that PAPP-A levels were significantly reduced in patients who developed these complications.27 Since data dispersion in the non-affected sample is high, as indicated by relatively large Standard Deviation values observed in our study, a clear flag-post value of PAPP-A level to indicate forthcoming PIH complication is difficult to establish.

In our study β hCG levels did not show any significant statistical correlation with PIH. The volume of placenta in PIH patients was marginally lower than the normal population mean. The difference in placental volume of PIH and Non-PIH patients was not statistically significant.

In present study, the serum PAPP-A levels showed statistically significant difference between Non-IUGR and IUGR groups. The observed PAPP-A levels of Non-IUGR group were 1.24±0.87 MoM, whereas that of IUGR group were 0.46±0.20 MoM. Since data dispersion in non-IUGR i.e., normal patients’ sample is high, as indicated by relatively large ‘Standard Deviation’ value, a clear flag-post value to predict imminent case of IUGR is difficult to establish.

There was no statistically significant difference in mean levels of the biomarker β-hCG between IUGR and Non-IUGR groups. The mean level of β-hCG in IUGR patients (1.0±0.64 MoM) was marginally lower in comparison to Non-IUGR patients (1.18±0.92 MoM). This is in line with study published by Dugoff et al. who evaluated pregnancies at 11-14 weeks of gestation and proved that maternal serum free β-hCG was mildly reduced in pregnancies that subsequently developed IUGR.28 Overall, the predictiveness of free β-hCG is unsatisfactory.29,30

Placental volume in the present study showed a p=0.07, with respect to development of IUGR. Placental volume of the Non-IUGR and IUGR outcome group were well separated - 48.16 and 24.35 cc respectively. Though the two-sample t-test did not show statistically significant difference at α=0.05 level of significance (p=0.07), evidence for failing to reject Null hypothesis is weak.

The limitations of our study were the small sample size, cost constraints and non-availability of advanced ultrasonography techniques. A larger sample size with a possibility of more patients with adverse pregnancy outcomes would be helpful in determining the statistical correlation between UAD indices and serum biomarkers and the development of PIH and IUGR. Low placental volume observed in cases of IUGR, though not statistically significant, could be further studied with 3D colour doppler for accurate measurement using larger sample size.

Recent advances in biochemical markers includes study of angiogenic and antiangiogenic factor levels that play profound role in pathophysiology of PIH. Angiogenic factors include VEGF, PIGF, whereas the antiangiogenic factors playing major role are sFlt-1 and soluble Endoglin. However, there is a severe cost constraint in utilization of these factors in low resource settings. Future studies are needed with inclusion of these newer biomarkers like sFlt-1, PIGF levels and their individual as well as combined correlation in prediction of PIH in a cost-effective manner.

**CONCLUSION**

The prospective observational study was conducted in our hospital to study predictive ability of Uterine Artery Doppler RI values, placental volume and levels of bio marker β-hcg and PAPP-A during 11th to 13th week of pregnancy to identify increased risk of PIH and IUGR.

The adverse pregnancy outcomes in our study, evaluated in terms of PIH and IUGR, occurred in 22.58% of patients.

In the IUGR patients, levels of PAPP-A showed statistically significant difference compared to non-IUGR. Serum PAPP-A levels were on the lower side (0.68±0.38) in PIH than the normal population (1.32±0.91) in the study and were statistically significant.
The results of our study thus indicate, that biomarker PAPP-A level is a good indicator for possible prediction of PIH and IUGR. Levels of β hCG and UAD-RI were not found to be good predictors of the condition. Placental volume can be further explored in view of observed p value being close to level of statistical significance (p=0.07, α=0.05).

The study highlights the use of combined approach using clinical data and routine tests like serum dual markers and ultrasound parameters in early prediction of PIH and IUGR. This in turn will be useful in initiation of prophylactic management early in the course of pregnancy to prevent these complications. The combined approach using clinical data, serum biochemical markers and biophysical parameters (ultrasound parameters, arterial blood pressure) promises increased predictive relevance.

ACKNOWLEDGMENTS

On behalf of all co-authors, the author wishes to thank her Head, Department of Obstetrics and Gynaecology, Professor Suvarna Khadilkar for her support and encouragement. Special thanks to all Consultants and staff of the Dept. of ObGyn and Ultrasoundography and to the patients who cordially participated in the study.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Vyas HG, Goyal RK, Vyas GM, Vyas BA, Shah SA. An Observational Study to Determine the Prevalence and Risk Factors Associated with Pregnancy Induced Hypertension in a Semi-Urban Town of India. The Indian Practitioner. 2017;70(12):16-20.
2. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24-43.
3. Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, Shackelford KA, Steiner C, Heuton KR, et al. Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384(9947):980-1004.
4. World Health Organization. The WHO application of ICD-10 to deaths during pregnancy, childbirth and puerperium: ICD-MM. World Health Organization; 2012.
5. Dunn PM. The search for perinatal definitions and standards. Acta PaediatrScand Suppl. 1985;319:7-16.
6. Romo A, Carceller R, Tobajas J. Intrauterine growth retardation (IUGR): epidemiology and etiology. Pediatr Endocrinol Rev. 2009;6(Suppl 3):332-6.
7. Donald Ian; Practical obstetric problems. 7th edition, Wolters Kluwer India Pvt. Ltd; New Delhi, 2014: 339-352.
8. Xiong X, Mayes D, Demianczuk N, Olson DM, Davidge ST, Newburn-Cook C, Saunders LD. Impact of pregnancy-induced hypertension on fetal growth. Ameri J Obstet Gynecol. 1999;180(1):207-13.
9. Jurkovic DA, Jauniaux ER, Kurjak AS, Hustin JE, Campbell ST, Nicolaides KH. Transvaginal color Doppler assessment of the uteroplacental circulation in early pregnancy. Obstetrics Gynecol. 1991;77(3):365-9.
10. Van den Elzen HJ, Cohen-Overbeek TE, Grobbée DE, Quartoer RW, Wladimirroff JW. Early uterine artery Doppler velocimetry and the outcome of pregnancy in women aged 35 years and older. Ultrasound in Obstetrics and Gynecology: The Official J International Society of Ultrasound in Obstetrics and Gynecol. 1995;5(5):328-33.
11. Harrington K, Goldfrad C, Carpenter RG, and Campbell S. Transvaginal uterine and umbilical artery Doppler examination of 12–16 weeks and the subsequent development of pre-eclampsia and intrauterine growth retardation. Ultrasound in Obstetrics and Gynecology: The Official Journal of the International Society of Ultrasound in Obstetr and Gynecol. 1997;9(2):94-100.
12. Korevaar TI, Steegers EA, de Rijke YB, Schalekamp-Timmermans S, Visser WE, Hofman A, Jaddoe VW, et al. Reference ranges and determinants of total hCG levels during pregnancy: the Generation R Study. European J Epidemiol. 2015;30(9):1057-66.
13. Patil M, Panchanadikar TM, Wagh G. Variation of papp-a level in the first trimester of pregnancy and its clinical outcome. J Obstetr Gynecol Ind. 2014;64(2):116-9.
14. Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11–13 weeks. Ultrasound in Obstetrics and Gynecol: The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecol. 2010;35(6):662-70.
15. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound in Obstetrics and Gynecol: The Official Journal of the International Society of Ultrasound in Obstetr Gynecol. 2009;33(1):23-33.
16. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53(5):812-8.
17. Stamnes KUM, Andersen FLE, Joergensen DKN, Stigum H, Nass O, Nystrad W. Maternal pre-pregnant body mass index, maternal weight change and offspring birthweight. Acta obstetricia et gynecologica Scandinavica. 2012;91(2):243-9.
18. Sajith M, Nimbargi V, Modi A, Sumariya R, Pawar A. Incidence of pregnancy induced hypertension and prescription pattern of antihypertensive drugs in pregnancy. Int J Pharma Sci Res. 2014;23:4.
19. Berhe AK, Kassa GM, Fekadu GA, Muche AA. Prevalence of hypertensive disorders of pregnancy in Ethiopia: a systemic review and meta-analysis. BMC pregnancy and childbirth. 2018;18(1):34.
20. Gomez O, Martinez JM, Figuera F, Del Rio M, Borobia V, Puerto B, Coll O, Cararach V, Vanrell JA. Uterine artery Doppler at 11–14 weeks of gestation to screen for hypertensive disorders and associated complications in an unselected population. Ultrasound in Obstetr Gynecol. 2005;26(5):490-4.
21. Pedroso MA, Palmer KR, Hodges RJ, da Silva Costa F, Rolnik DL. Uterine artery Doppler in screening for preeclampsia and fetal growth restriction. Revista Brasileira de Ginecologiae Obstetricia/RBGO Gynecol Obstetr. 2018;40(05):287-93.
22. Azpurua H, Funai EF, Coraluzzi LM, Doherty LF, Sasson IE, Kliman M, Kliman HJ. Determination of placental weight using two-dimensional sonography and volumetric mathematical modeling. American J Perinatol. 2010;27(02):151-5.
23. Shiefa S, Amargandhi M, Blupendra J, Moulali S, Kristine T. First trimester maternal serum screening using biochemical markers PAPP-A and free ß-hCG for down syndrome, patau syndrome and edward syndrome. Ind J Clinic Biochemist. 2013;28(1):3-12.
24. Bapat A. Role of Dual Biomarkers & Ut. artery Doppler study in predicting PIH & IUGR. Dissertation submitted to the Maharashtra University of Health Sciences; 2019.
25. Muti M, Tshimanga M, Notion GT, Bangure D, Chonzi P. Prevalence of pregnancy induced hypertension and pregnancy outcomes among women seeking maternity services in Harare, Zimbabwe. BMC cardiovascular disorders. 2015;15(1):111.
26. Scandiuzzi RM, Prado CA, Araujo Júnior E, Duarte G, Quintana SM, da Silva Costa F, Tonni G, Cavalli RD, et al. Maternal uterine artery Doppler in the first and second trimesters as screening method for hypertensive disorders and adverse perinatal outcomes in low-risk pregnancies. Obstetr Gynecol Sci. 2016;59(5):347-56.
27. Abdel Moety GA, Almohamady M, Sherif NA, Raslana AN, Mohamed TF, El Moneam HM, et al. Could first-trimester assessment of placental functions predict preeclampsia and intrauterine growth restriction? A prospective cohort study. The Journal of Maternal-Fetal & Neonatal Medic. 2016;29(3):413-7.
28. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). American J Obstetrics and Gynecol. 2004;191(4):1446-51.
29. Gardosi J. Intrauterine growth restriction: new standards for assessing adverse outcome. Best practice & research Clinic Obstetr Gynaecol. 2009;23(6):741-9.
30. Gardosi J. Customised assessment of fetal growth potential: implications for perinatal care. Archives of Disease in Childhood-Fetal and Neonatal Edition. 2012;97(5):F314-7.
31. Popovski N, Nikolov A. Biomarkers for Early Detection of Hypertensive Disorders in Pregnancy: Current Applications and Future Directions-The Role of Extracellular Matrix. Biomedical J Scient Technic Res. 2019;16(2):1-3.

Cite this article as: Bapat AC, Kashikar R, Goyal SR. Role of dual biomarkers and uterine artery doppler study in predicting PIH and IUGR in antenatal patients registered in a tertiary care centre. Int J Reprod Contracept Obstet Gynecol 2021;10:982-7.